

Disclaimers

1. The results of this cost calculator are based on estimates and do not represent confirmed observations. In addition, inaccurate data input can lead to misleading conclusions. This calculator has not been validated by a prospective study. The results of the calculator do not guarantee the financial or clinical performance of any anti-obesity medication mentioned within it.
2. This cost calculator is intended for presentation to a payor, formulary committee, or other similar entity carrying out its responsibilities for the selection of drugs for coverage or reimbursement on behalf of healthcare organization.
3. Novo Nordisk is providing you with this material as an information service and professional courtesy. Providing this scientific information does not constitute any recommendation for use. Prescription drugs used in a manner other than their approved indication may not be eligible for reimbursement by any third-party payers.

References for Model

- Adult enrollment in UT Medicaid (*assume 10% loss from current adult enrollment due to redetermination*): [January 2023 Medicaid & CHIP Enrollment Data Highlights | Medicaid](#)
- Adults with obesity in UT: [Adult Obesity Prevalence Maps | Overweight & Obesity | CDC](#)
- Utah's FMAP is 65.90%: [Federal Medical Assistance Percentage \(FMAP\) for Medicaid and Multiplier | KFF](#)
- Drug market shares are estimates for the U.S. Medicaid channel: [State Drug Utilization Data | Medicaid](#)
- Rebate percentages include estimates for URA, supplemental, and Federal Match (FMAP)
- Wegovy[®] prescribing information: [Wegovy PI \(novo-pi.com\)](#)
- Saxenda[®] prescribing information: [Saxenda PI \(novo-pi.com\)](#)

Population

	Percentage	# of Lives
Plan size		217,288
Adults with obesity (%); BMI ≥ 30	35.0%	76,051
Adults who are overweight (%); BMI 25.0 - 29.9	31.1%	67,577
Adults with BMI 27.0-29.0 (%)	59.8%	40,411
Eligible adults with BMI 27.0 - 29.0 & 1+ weight-related comorbidities* (%)	77.1%	31,157
Total adults eligible for AOM use		107,207
AOM utilization rate	1.0%	1,072

*Includes diabetes, dyslipidemia, hypertension, obstructive sleep apnea, urinary incontinence, and asthma.

Please [click here](#) for Wegovy® Prescribing Information, including Boxed Warning.

Please [click here](#) for Saxenda® Prescribing Information, including Boxed Warning.

Market Mix

Market share take:

Brand	WAC per 30 days	Total share	Branded Share
Contrave	\$625.20	1.0%	1.2%
Qsymia (15 - 92mg)	\$199.50	1.0%	1.2%
Saxenda® (liraglutide) injection 3 mg	\$1,349.02	7.0%	8.2%
Wegovy® (semaglutide) injection 2.4 mg	\$1,349.02	75.0%	88.2%
Xenical	\$753.71	1.0%	1.2%
Generic use*	\$46.07	15.0%	
Branded AOM blended costs	\$1,319.98		
Total blended cost	\$1,128.89	100.0%	

Adults utilizing branded AOM 911

Adults utilizing generic AOM 161

*Includes diethylpropion, phentermine, benzphetamine, and phendimetrazine

Estimates Only - Actual values may Be Different

Duration of Therapy (DOT)

	DOT (months)	
Contrave	3	<input type="button" value="▲"/> <input type="button" value="▼"/>
Qsymia (15 - 92mg)	3	<input type="button" value="▲"/> <input type="button" value="▼"/>
Saxenda® (liraglutide) injection 3 mg	6	<input type="button" value="▲"/> <input type="button" value="▼"/>
Wegovy® (semaglutide) injection 2.4 mg	6	<input type="button" value="▲"/> <input type="button" value="▼"/>
Xenical	3	<input type="button" value="▲"/> <input type="button" value="▼"/>
Generic	3	<input type="button" value="▲"/> <input type="button" value="▼"/>

Rx Utilization per year

Total Contrave Rx	32
Total Qsymia (15 - 92mg) Rx	32
Total Saxenda® (liraglutide) injection 3 mg Rx	450
Total Wegovy® (semaglutide) injection 2.4 mg Rx	4,824
Total Xenical Rx	32
Total generic* Rx	482

*Includes diethylpropion, phentermine, benzphetamine, and phendimetrazine

Please [click here](#) for Wegovy® Prescribing Information, including Boxed Warning.

Please [click here](#) for Saxenda® Prescribing Information, including Boxed Warning.

Basic Results

	Annual Costs	DOT-adjusted Costs
Estimated total yearly cost	\$14,523,065.48	\$7,188,541.82
Estimated PMPY cost	\$66.84	\$33.08
Estimated PMPM cost	\$5.57	\$2.76

Results including rebate

Contrave Rebate	50.0%
Qsymia (15 - 92mg) Rebate	50.0%
Saxenda® (liraglutide) injection 3 mg Rebate	75.0%
Wegovy® (semaglutide) injection 2.4 mg Rebate	75.0%
Xenical Rebate	50.0%
Generic Rebate	43.0%

Please [click here](#) for Wegovy® Prescribing Information, including Boxed Warning.

Please [click here](#) for Saxenda® Prescribing Information, including Boxed Warning.

	Annual Costs	DOT-adjusted Costs
Estimated total yearly cost	\$3,709,980.49	\$1,816,938.99
Estimated PMPY cost	\$17.07	\$8.36
Estimated PMPM cost	\$1.42	\$0.70